Skin Allergies: October 2006 Archives

Sun allergy drug set for phase II US trials

|

Sun Pharma Advanced Research Company (Sparc), the recently demerged research entity of domestic pharma major Sun Pharmaceutical, is all set to take its lead molecule for anti-allergic treatment to the phase-II trials (trials on patient) in the US.

The investigational new drug (IND) of Sparc has already received permission from the US Food and Drug Administration to enter the phase-II trials.

The phase-II trials will be conducted in the US directly by the company, using a leading local CRO (clinical research organisation). This will mark the first IND filing and phase-II studies in the US by an Indian company working independently, that’s without a partner.